Clinical Trial Update: Neoadjuvant ADT with TULSA in the Treatment of Intermediate Risk Prostate Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating neoadjuvant androgen deprivation therapy (ADT) in combination with the TULSA device for intermediate-risk localized prostate cancer is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Androgen deprivation therapy (Androgen deprivation therapy)

Snippet

Sponsor: Turku University Hospital | Conditions: Localized Prostate Carcinoma, Castration-Naive Prostate Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING